课题基金 / 基金详情

Development of tumor-targeted therapy using measles virus-displayed antibody library

Development of tumor-targeted therapy using measles virus-displayed antibody library
利用麻疹病毒展示抗体库开发肿瘤靶向治疗
批准号:
22659227
负责人:
NAKAMURA Takafumi
金额:
$2.06万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Challenging Exploratory Research
财政年份:
2010
资助国家:
日本
项目状态:
已结题
起止时间:
2010 至 2011

项目摘要

项目成果

NAKAMURA Takafumi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We have successfully developed a pseudoreceptor system which allows rescue and propagation of retargeted viruses displaying single chain antibody fragments(scFvs). Thus, receptor choice is not a significant limitation for targeting measles viruses and the use of single chain antibodies for targeting potentially allows us to redirect the virus against any chosen cellular receptor.In this study, we try to develop measles virus-displayed scFv library(virobody library) using the technology for identification of tumor-specific scFv. Human A549 lung, or BxPC-3 pancreatic carcinoma cells were infected with virobody library at an MOI of 0. 01 to 1, one hour later the cells were washed with Opti-MEM medium(Invitrogen) four times. 2 to 5 days after infection, propagated viruses were harvested by repeated freeze-thaw cycles from the GFP-positive infected cells. The biopanning was repeated several times, and finally the tumor-targeted measles virus was cloned from the GFP-positive infected cells. The cDNA encoding scFv from the viral RNA genome was amplified by RT-PCR for sequence analysis. However, the identified scFvs were not functional as a tumor-specific antibody. We have assumed that the diversity of measles virus-displayed scFv library is not sufficient enough to identify tumor-specific scFvs. To address this question, not traditional ligation method but Gateway[○! R] Technology-based cloning method(Invitrogen) was used for generation of plasmid library. Various kind of scFvs were incorporated into the C terminus of a receptor-blind H gene in a full-length cDNA clone of Edmonston measles virus. Furthermore, infectious scFv-displaying measles viruses were rescued from the full-length cDNA clones using helper vaccinia virus expressing T7 RNA polymerase. These modifications dramatically increased the diversity of measles virus-displayed scFv library.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1186/1472-6750-10-37
发表时间: 2010-05-06
期刊: BMC biotechnology
影响因子: 3.5
作者: [Katoh M, Kazuki Y, Kazuki K, Kajitani N, Takiguchi M, Nakayama Y, Nakamura T, Oshimura M]
通讯作者: Oshimura M
DOI: --
发表时间: 2010
期刊:
影响因子: --
作者: [Sawada Y, Sugita K, Kabashima R, Hino R, Nakamura M, Koga C, Tokura Y, 高橋昭久, 中村貴史]
通讯作者: 中村貴史
MicroRNA Targeting of Oncolytic Viruses for cancer therapy
用于癌症治疗的溶瘤病毒的 MicroRNA 靶向
DOI: --
发表时间: 2011
期刊:
影响因子: --
作者: [Takafumi Nakamura.]
通讯作者: Takafumi Nakamura.
Highly Attenuated Vaccinia Virus as a Potential Oncolytic Agent for Cancer Virotherapy
高度减毒痘苗病毒作为癌症病毒治疗的潜在溶瘤剂
DOI: --
发表时间: 2010
期刊:
影响因子: --
作者: [Fusasaki T, Narita R, Hiura M, Abe S, Tabaru A, Hino R, Matsuyama A, Shimajiri S, Tokura Y, Sasaguri Y, Harada M, Nakamura T]
通讯作者: Nakamura T
17
    Novel strategy of cancer virotherapy for radical cure of both primary and metastatic tumors
    • 批准号:
      19H03515
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.07万
    • 财政年份:
      2019
    • 负责人:
      NAKAMURA Takafumi
    • 依托单位:
    A novel oncolytic virotherapy for paclitaxel resistant ovarian cancer
    • 批准号:
      17K19597
    • 项目类别:
      Grant-in-Aid for Challenging Research (Exploratory)
    • 资助金额:
      $4.08万
    • 财政年份:
      2017
    • 负责人:
      NAKAMURA Takafumi
    • 依托单位:
    Tumor-targeted MAPK-dependent recombinant vaccinia virus for oncolytic virotherapy
    • 批准号:
      15H04310
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.82万
    • 财政年份:
      2015
    • 负责人:
      NAKAMURA Takafumi
    • 依托单位:
    Development of tumor-targeted therapy using lentivirus-displayed antibody library
    • 批准号:
      24650629
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2012
    • 负责人:
      NAKAMURA Takafumi
    • 依托单位:
    国内基金
    海外基金
    瘤内链球菌促进STAT3的O-GlcNAc修饰驱动鼻咽癌免疫抑制微环境的机制研究
    • 批准号:
      JCZRLH202600778
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    SDC1通过MMP11+CAF的细胞外基质重塑促进子宫颈癌化学免疫联合治疗耐药的机制研究
    • 批准号:
      JCZRQNB202600504
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    多模态精准导航引导肝内胆管癌淋巴结清扫的动态示踪与机制探索
    抗BNLF2b抗体联合circRNA构建鼻咽癌早期诊断模型及机制研究